MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Apellis Pharmaceuticals ROE Ratio 2011-2026 | APLS
Annual ROE Ratio Apellis Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.58 | -271.76 | -383.92 | -375.69 | -168.6 | -890.18 | -79.21 | -34.25 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -34.25 | -890.18 | -286.27 |
Quarterly ROE Ratio Apellis Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -131.58 | -118.86 | -63.38 | -123.76 | -159.91 | -180.99 | -138.85 | -201.06 | -202.91 | -120.93 | -45.63 | 295.53 | 698.91 | 807.18 | 140.55 | 178.81 | -228.69 | -441.59 | -168.6 | -537.62 | -675.28 | -824.98 | -890.2 | -582.08 | -400.44 | -213.46 | -79.21 | -68.81 | -54.24 | -41.67 | -34.25 | -49.81 | -72.34 | -64.2 | -58.13 | -30.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 807.18 | -890.2 | -135.63 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Amarin Corporation plc
AMRN
|
-10.71 | $ 15.03 | 1.9 % | $ 6.13 B |  Irlanda |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.85 | 3.55 % | $ 4.64 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
-66.16 | $ 2.96 | 10.86 % | $ 167 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.57 | - | $ 8.59 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 220.67 | -0.61 % | $ 5 B |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 110.85 | 0.46 % | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
-28.65 | $ 2.64 | 8.2 % | $ 3.08 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.18 | 2.28 % | $ 1.47 B | Britain |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Compugen Ltd.
CGEN
|
-25.92 | $ 1.78 | 4.06 % | $ 159 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 4.53 | 5.93 % | $ 9.86 B | Israel |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.47 | 0.34 % | $ 375 M | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
67.61 | $ 14.63 | 0.72 % | $ 4.52 B | USA |
 |
Codexis
CDXS
|
-97.53 | $ 1.28 | -0.78 % | $ 94 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |